LXEO

Lexeo Therapeutics, Inc.

Lexeo Therapeutics, Inc. (LXEO) has 13 SEC Form 4 filings (17 transaction rows) in the rolling window, disclosed by 4 distinct insiders. Most recent filing: Jul 1, 2026.

The most active filer is Chief Operating Officer Otero Jose Manuel with 4 filings. Insiders have net sold $684K over the trailing 6 months.

  • Industry:Biotechnology
  • CEO:R. Nolan Townsend
  • Employees:75
  • HQ:New York City, US
  • IPO:2023-11-03

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$684K

reported sales (SEC code S)

Unique Insiders

4

in the rolling window

Market Cap

$357.3M

latest known value

Source
Sale$21KJul 1SEC ↗
Sale$21KJul 1SEC ↗
Sale$99KJul 1SEC ↗
Sale$116KJul 1SEC ↗
Sale$17KMay 20SEC ↗
Sale$7KMay 20SEC ↗
Sale$313KApr 7SEC ↗
Otero Jose ManuelFirst filing
Sale$7KFeb 20SEC ↗
Otero Jose ManuelFirst filing
Sale$19KFeb 20SEC ↗
Sale$65KFeb 20SEC ↗

Related companies

Lexeo Therapeutics, Inc. is in the Healthcare sector.